Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Dasatinib
60
CHF
CHF 60.00
In stock
SYN-1036-M0011 mgCHF 60.00
SYN-1036-M0055 mgCHF 78.00
SYN-1036-M01010 mgCHF 108.00
SYN-1036-M05050 mgCHF 239.00
SYN-1036-M100100 mgCHF 383.00

Product Details | |
---|---|
Synonyms | BMS-354825; Sprycel |
Product Type | Chemical |
Properties | |
Formula | C22H26ClN7O2S |
MW | 488.0 |
CAS | 302962-49-8 |
Purity Chemicals | ≥95% |
Appearance | Solid. |
Solubility | Soluble in DMSO or ethanol. |
Declaration | Manufactured by SynKinase. |
Other Product Data |
Target: Abl - BCR - BTK | Kinase Group: PTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
InChi Key | ZBNZXTGUTAYRHI-UHFFFAOYSA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS |
![]() |
Product Specification Sheet | |
Datasheet |
![]() |
The BCR-ABL oncogene triggers intracellular signaling, activating multiple transduction cascades, promoting the growth, proliferation and survival of hematopoietic cells. BCR-ABL plays a role in defective DNA repair, alteration of cellular adhesion and inhibition of apoptosis. Degregulated BCR-ABL tyrosine kinase activity is the molecular marker for CML. Inhibiting BCR-ABL tyrosine kinase activity leads to the induction of apoptosis and inhibits cellular proliferation in vitro and there are various BCR-ABL isoforms with differing activity levels as well. Dasatinib (BMS-354825, Sprycel®) is a potent multi-target kinase inhibitor of BCR-ABL. Dasatiinib performs better against ABL kinase than earlier drugs such as imatinib, and Dasatinib also is effective against SRC family of kinases, and other receptor kinases such as EPHA2, PDGFR, and c-Kit. Dasatinib's inhibiting potential against Src family kinase members is greater (IC(50) 0.5nM) than its inhibitory activity against ABL (1nM).
Product References
- 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor: J. Das, et al.; J. Med. Chem. 49, 6819 (2006)
- Dasatinib in chronic myeloid leukemia: a review: D.G. Aguilera & A.M. Tsimberidou; Ther. Clin. Risk. Manag. 5, 281 (2009)
- Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib: X. Ren, et al.; J. Med. Chem. 56, 879 (2013)